198 related articles for article (PubMed ID: 30771580)
21. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.
Piccio L; Naismith RT; Trinkaus K; Klein RS; Parks BJ; Lyons JA; Cross AH
Arch Neurol; 2010 Jun; 67(6):707-14. PubMed ID: 20558389
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Leptomeningeal Contrast Enhancement Using Pre-and Postcontrast Subtraction 3D-FLAIR Imaging in Multiple Sclerosis.
Zivadinov R; Ramasamy DP; Hagemeier J; Kolb C; Bergsland N; Schweser F; Dwyer MG; Weinstock-Guttman B; Hojnacki D
AJNR Am J Neuroradiol; 2018 Apr; 39(4):642-647. PubMed ID: 29439125
[TBL] [Abstract][Full Text] [Related]
23. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.
Elliott C; Belachew S; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Fecker J; Model F; Wei W; Arnold DL
Brain; 2019 Sep; 142(9):2787-2799. PubMed ID: 31497864
[TBL] [Abstract][Full Text] [Related]
24. [Primary progressive multiple sclerosis: a treatment turns out to be finally effective].
Lalive PH
Rev Med Suisse; 2016 Mar; 12(508):472-3. PubMed ID: 27089606
[No Abstract] [Full Text] [Related]
25. CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.
Romme Christensen J; Komori M; von Essen MR; Ratzer R; Börnsen L; Bielekova B; Sellebjerg F
Mult Scler; 2019 Jun; 25(7):937-946. PubMed ID: 29775134
[TBL] [Abstract][Full Text] [Related]
26. Rituximab in multiple sclerosis at general hospital level.
Hellgren J; Risedal A; Källén K
Acta Neurol Scand; 2020 Jun; 141(6):491-499. PubMed ID: 31990978
[TBL] [Abstract][Full Text] [Related]
27. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
Axelsson M; Malmeström C; Gunnarsson M; Zetterberg H; Sundström P; Lycke J; Svenningsson A
Mult Scler; 2014 Jan; 20(1):43-50. PubMed ID: 23702432
[TBL] [Abstract][Full Text] [Related]
28. Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis.
Ratzer R; Iversen P; Börnsen L; Dyrby TB; Romme Christensen J; Ammitzbøll C; Madsen CG; Garde E; Lyksborg M; Andersen B; Hyldstrup L; Sørensen PS; Siebner HR; Sellebjerg F
Mult Scler; 2016 Jun; 22(7):926-34. PubMed ID: 26432857
[TBL] [Abstract][Full Text] [Related]
29. Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.
Naegelin Y; Naegelin P; von Felten S; Lorscheider J; Sonder J; Uitdehaag BMJ; Scotti B; Zecca C; Gobbi C; Kappos L; Derfuss T
JAMA Neurol; 2019 Mar; 76(3):274-281. PubMed ID: 30615019
[TBL] [Abstract][Full Text] [Related]
30. Inflammatory intrathecal profiles and cortical damage in multiple sclerosis.
Magliozzi R; Howell OW; Nicholas R; Cruciani C; Castellaro M; Romualdi C; Rossi S; Pitteri M; Benedetti MD; Gajofatto A; Pizzini FB; Montemezzi S; Rasia S; Capra R; Bertoldo A; Facchiano F; Monaco S; Reynolds R; Calabrese M
Ann Neurol; 2018 Apr; 83(4):739-755. PubMed ID: 29518260
[TBL] [Abstract][Full Text] [Related]
31. Intrathecal IgM synthesis in pediatric MS is not a negative prognostic marker of disease progression: quantitative versus qualitative IgM analysis.
Stauch C; Reiber H; Rauchenzauner M; Strasak A; Pohl D; Hanefeld F; Gärtner J; Rostásy KM
Mult Scler; 2011 Mar; 17(3):327-34. PubMed ID: 21123302
[TBL] [Abstract][Full Text] [Related]
32. Lower dosages of rituximab used successfully in the treatment of anti-NMDA receptor encephalitis without tumour.
Wang BJ; Wang CJ; Zeng ZL; Yang Y; Guo SG
J Neurol Sci; 2017 Jun; 377():127-132. PubMed ID: 28477682
[TBL] [Abstract][Full Text] [Related]
33. Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis.
Absinta M; Vuolo L; Rao A; Nair G; Sati P; Cortese IC; Ohayon J; Fenton K; Reyes-Mantilla MI; Maric D; Calabresi PA; Butman JA; Pardo CA; Reich DS
Neurology; 2015 Jul; 85(1):18-28. PubMed ID: 25888557
[TBL] [Abstract][Full Text] [Related]
34. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.
de Flon P; Gunnarsson M; Laurell K; Söderström L; Birgander R; Lindqvist T; Krauss W; Dring A; Bergman J; Sundström P; Svenningsson A
Neurology; 2016 Jul; 87(2):141-7. PubMed ID: 27316241
[TBL] [Abstract][Full Text] [Related]
35. PET-measurable innate immune cell activation reduction in chronic active lesions in PPMS brain after rituximab treatment: a case report.
Lehto J; Sucksdorff M; Nylund M; Raitanen R; Matilainen M; Airas L
J Neurol; 2023 Apr; 270(4):2329-2332. PubMed ID: 36576574
[TBL] [Abstract][Full Text] [Related]
36. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.
Hawker K; O'Connor P; Freedman MS; Calabresi PA; Antel J; Simon J; Hauser S; Waubant E; Vollmer T; Panitch H; Zhang J; Chin P; Smith CH;
Ann Neurol; 2009 Oct; 66(4):460-71. PubMed ID: 19847908
[TBL] [Abstract][Full Text] [Related]
37. Contrast-enhanced fat-suppressed FLAIR for the characterization of leptomeningeal inflammation in optic neuritis.
Pino-Lopez L; Wenz H; Böhme J; Maros M; Schlichtenbrede F; Groden C; Förster A
Mult Scler; 2019 May; 25(6):792-800. PubMed ID: 29683029
[TBL] [Abstract][Full Text] [Related]
38. Leptomeningeal Enhancement at 7T in Multiple Sclerosis: Frequency, Morphology, and Relationship to Cortical Volume.
Harrison DM; Wang KY; Fiol J; Naunton K; Royal W; Hua J; Izbudak I
J Neuroimaging; 2017 Sep; 27(5):461-468. PubMed ID: 28464368
[TBL] [Abstract][Full Text] [Related]
39. Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension.
Bergman J; Burman J; Bergenheim T; Svenningsson A
J Neurol; 2021 Feb; 268(2):651-657. PubMed ID: 32901316
[TBL] [Abstract][Full Text] [Related]
40. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.
Magliozzi R; Howell O; Vora A; Serafini B; Nicholas R; Puopolo M; Reynolds R; Aloisi F
Brain; 2007 Apr; 130(Pt 4):1089-104. PubMed ID: 17438020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
